


Background We observed a high number of patients admitted with suspected pulmonary embolism (PE) via our acute medical unit. After positive diagnosis, they remained as inpatients until their International Normalised Ratio (INR) was in range resulting in long lengths of stay - Median (range) 7 (0 to 52) days. Recently, there has been increasing interest in ambulatory management providing high quality cost-effective care.

Objectives To develop a care pathway for suspected PE incorporating prognostic scoring to assist ambulatory same-day management. To assess cost effectiveness of such a strategy in terms of bed day release whilst ensuring that it did not adversely affect safety by misclassification of patients.

Method We formulated an ambulatory pathway (figure1) with an algorithm comprising of the simplified PESI (pulmonary embolism severity index) score and serum Troponin I measurement with various exclusion criteria to identify patients fit for ambulatory management. Over a 3-month period, 191 patients underwent computerised tomography pulmonary angiogram (CTPA) for suspected PE. 28/191 patients were excluded from analysis as they were outpatients or pre-existing inpatients. We retrospectively applied the pathway to the remaining 163 patients. To assess the impact of the pathway, we measured increase in the number of patients that could have been managed using same-day emergency care, incremental bed day release and benefits derived via the enhanced tariff through Payment by Results (PbR). Safety was assessed by noting mortality within the ambulatory group identified.

Results 73/163 (44%) patients were male and mean (SD) age was 62 (17.8) years. Using our pathway, 36/163 (22%) of all suspected PEs could have been managed within a zero-day admission. 5/36 (14%) with a definite PE could have been managed as ambulatory patients. A mean incremental stay of 4 days for the 36 patients equates to 144 bed days released over the 3-month period. The PbR additional income on completion of a same-day emergency management would add £225/patient to savings made. None of the patients selected for ambulatory management via the pathway suffered any adverse events.

Conclusion We have successfully developed and implemented an effective ambulatory management strategy for suspected PE. A validity study is planned.



Abstract P153 Figure 1.

P154 OUTPATIENT MANAGEMENT OF PULMONARY EMBOLISM-PATIENT CHARACTERISTICS AND OUTCOMES

A Lakhanpal, C Watters, C Hughes, S Iyer, M Babores; *Macclesfield District General Hospital, Macclesfield, UK*

10.1136/thoraxjnl-2013-204457.304

Introduction Management of Pulmonary Embolism (PE) has been until recently largely in-patient based and markedly affects length of stay in these patients. Recent evidence suggests that suspected or confirmed cases of PE can be managed out of hospital^{1, 2}. We present our experience of outpatient management of PE in a small district general hospital.

Method We identified 35 patients investigated/treated for PE as outpatient between March 2012 and June 2013. Demographic and clinical data was collected from case notes. Statistical analysis was performed on Medcalc based on normality.

Result The table below profiles our cohort. (Table)

There was a high PE diagnosis (51%) within our cohort despite most patients being in a low PESI class. Clinical decision made in high PESI class to manage as outpatient. PE was diagnosed in 4 of the 5(80%) patients with a raised Troponin level (odds ratio 1.66, statistically not significant). Out of 21 GP referrals, 13(61.9%) had a positive scan as opposed to 5 of the 13 (38.4%) patients referred from hospital, however this did not attain statistical significance (odds ratio 3.25, p = 0.12). The equivocal CTPA was deemed not PE on clinical grounds. All patients were reviewed by a Registrar or Consultant prior to discharge. No mortality recorded till date. One patient re-presented with exacerbation of Asthma.

Discussion Carefully selected patients with suspected or confirmed PE can be managed out of hospital. Based on time to imaging, at least 28 unnecessary inpatient days were avoided leading to £9800 saved and a high pick up rate. In our experience, mortality and re-admission rates have been minimal highlighting outpatient management as a safe and cost-effective strategy in management of PE.

REFERENCES

1. Safety of outpatient treatment in acute pulmonary embolism. Erkens PM, Gandara E, Wells P, et al. *J Thromb Haemost*, Nov 2010, vol/iss. 8/11(2412-7), 1538-7836
2. Outpatient Management of suspected Pulmonary Embolism at a District General Hospital; A Two Month Review. JA Benjamin, A Griffiths, S power, et al. *Thorax* 2012;67:A123 doi:10.1136/thoraxjnl-2013-204457.305

Abstract P154 Table 1.

Referral source-number of patients	General Practice-17, A&E-10, Clinics-4
Time of assessment	Out of Hours-18, Working hours-17
Sex	Females-25, Male-10
Age-Mean(SD)	51.26(18.85)
D-dimer, range(Median)	50-6793(512)
Positive Troponin	5/30 (16.6%) (not done in 5 cases)
PESI Class 1-2(low risk)	33/35 (94.2%)
CTPA done in 24 hours	24/35 (68.5%)
Result	Positive-18, Negative-16, Equivocal-1

SD-Standard Deviation. PESI- Pulmonary Embolism Severity Index.

P155 ARE WE UTILISING CT PULMONARY ANGIOGRAPHY APPROPRIATELY IN THE DIAGNOSIS OF SUSPECTED PULMONARY EMBOLISM? A THREE MONTH REVIEW IN A DISTRICT GENERAL HOSPITAL

SE Fernandes, N McDonald; *Borders General Hospital, Melrose, UK*

10.1136/thoraxjnl-2013-204457.306

Introduction CT pulmonary angiography (CTPA) is the recommended imaging modality for suspected pulmonary embolism (PE). Current NICE guidelines recommend using clinical prediction scoring systems to estimate the probability of PE and guide further investigation[1]. A low or intermediate probability score, coupled with a negative D-dimer, reliably excludes PE, thereby avoiding the need for CTPA.

Objectives We undertook a retrospective audit to examine adherence to NICE guidelines for diagnosis of suspected PE in patients admitted to a district general hospital, and identify patients who may have undergone unnecessary CTPA.

Methods We obtained a list of all CTPAs undertaken in our hospital between December 2012 and February 2013. D-dimer tests are poorly specific within hospitalised patients; therefore, we excluded post-surgical and obstetric patients, and pre-existing inpatients where primary admission was not for suspected PE. We also excluded outpatient CTPAs. We searched the records for contemporaneous PE probability scores and D-dimer results. For patients without a probability score result, we reviewed the clinical notes and calculated a probability score retrospectively using a local scoring system adapted from BTS guidelines.

Results There were 115 CTPAs during the study period – 36 were excluded and 4 patients' case notes were unavailable. 75 patients fulfilled the inclusion criteria (mean age 68.2 years), and PE was confirmed in 20%. 50 patients (66.7%) had a contemporaneous documented clinical probability score. There were 5 patients (6.7%) with a low/intermediate probability score and negative D-dimer, who underwent unnecessary CTPA (PE excluded in each case). There were 9 patients (12%) with retrospectively calculated low/intermediate clinical probability scores and no D-dimer result, who may have avoided CTPA had D-dimer been undertaken (CTPA excluded PE in each case).

Conclusions In our district general hospital, the underuse of clinical probability scoring and D-dimer testing in patients with suspected PE is contributing to unnecessary CTPAs. Introducing mandatory documentation of PE clinical probability score on CTPA request forms may reduce the number of unnecessary CTPAs.

REFERENCES

1. National Institute for Health and Clinical Excellence (2012) Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical Guideline 144. London: NICE.

P156

NEUTROPHIL AND REDOX DEPENDENT PROTEOLYSIS OF BONE MORPHOGENETIC PROTEIN 9: POTENTIAL ROLE IN THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION

W Li, K Hoenderdos, RM Salmon, PD Upton, AM Condliffe, ER Chilvers, NW Morrell; Department of Medicine, University of Cambridge, Cambridge, UK

10.1136/thoraxjnl-2013-204457.307

Introduction A critical reduction of bone morphogenetic protein type II receptor (BMPRII) in the pulmonary circulation, either due to the genetic loss-of-function mutations, heightened inflammation or prolonged hypoxia, is one of the major causes behind pulmonary arterial hypertension (PAH), a fatal disease with poor prognosis. BMPRII is highly expressed in the vascular endothelium and undergoes rapid turnover. Bone morphogenetic protein 9 (BMP9), the only active circulating BMP, signals via endothelial BMPRII, inducing BMPRII expression and maintaining endothelial homeostasis. Although BMPRII function has been studied

extensively, factors that regulate BMP9 stability and activity remain unclear.

Objective To investigate how BMP9 activity and stability are regulated and whether this regulation plays a role in pulmonary arterial hypertension.

Results Two forms of BMP9 dimer could be co-purified, with (D-form) or without (M-form) intermolecular disulphide bond. M- and D-forms BMP9 are interchangeable with redox potential, but have different stability. While the M-form is more susceptible to redox-dependent cleavage and proteases present in serum, the D-form is a preferred substrate for neutrophil elastase. Freshly isolated human peripheral blood neutrophils, when activated by hypoxia or inflammatory stimuli, released elastase that cleaved BMP9 effectively.

Conclusions and Discussions This study demonstrates a novel proteolytic regulation of BMP9 under physiological and pathological conditions, suggesting neutrophil elastase could be a potential link between inflammation/hypoxia and BMPRII signalling, and the recognised benefits of elastase inhibition in rodent models of PAH may be due in part to reduced degradation of BMP9 and preservation of endothelial BMPRII signalling.

P157

HEPATOCTY GROWTH FACTOR CONCENTRATION CORRELATES WITH HAEMODYNAMIC SEVERITY IN CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION

¹R Condliffe, ¹CA Elliot, ²I Sabroe, ³RT Zamanian, ⁴A Morton, ⁵AJ Swift, ¹DG Kiely, ⁶A Lawrie; ¹Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK; ²Department of Infection and Immunity, University of Sheffield, Sheffield, UK; ³Stanford University, Palo Alto, USA; ⁴Department of Cardiology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK; ⁵Academic Unit of Radiology, University of Sheffield, Sheffield, UK; ⁶Department of Cardiovascular Science, University of Sheffield, Sheffield, UK

10.1136/thoraxjnl-2013-204457.308

Introduction Hepatocyte growth factor (HGF) acts via the tyrosine kinase receptor, c-MET, on endothelial and epithelial cells. It has angiogenic, mitogenic, motogenic and anti-apoptotic effects. Administration of HGF has been shown to ameliorate pulmonary arterial hypertension (PAH) in the monocrotaline rat model.^{1,2} Little is known regarding circulating HGF levels in human disease.

Methods 47 incident, treatment naive patients with PAH in association with connective tissue disease (CTD-PAH) had blood sampling at or within 1 day of diagnostic right heart catheterisation. Plasma HGF concentrations were measured using Bio-Plex bead array. A proportion of patients also had NT-proBNP measured and underwent cardiac MRI.

Results Baseline characteristics were (mean, sd): Age 64(10)yrs, mean right atrial pressure (mRAP) 9.6(11.7)mmHg, mean pulmonary arterial pressure (mPAP) 40.6(13)mmHg, pulmonary arterial wedge pressure 10.5(4.5)mmHg, cardiac index (CI) 2.97 (0.7)L/min, pulmonary vascular resistance (PVR) 531(350)dyns. HGF levels correlated positively with mRAP (0.6, $r < 0.001$), mPAP ($r = 0.68$, $p < 0.001$: fig 1), PVR ($r = 0.51$, $p = 0.001$) and negatively with CI ($r = -0.43$, $p = 0.008$) and right ventricular ejection fraction measured by MRI ($r = -0.53$, $p = 0.034$). N-terminal pro B-type natriuretic peptide (NT-proBNP) measured in approximately 50% of patients correlated more strongly with CI ($r = -0.72$, $p < 0.001$) and PVR ($r = 0.61$, $p = 0.003$) but did not correlate with mPAP. A small proportion (7) of patients underwent repeat right heart catheterisation (RHC)